TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01757340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss with protein/leucine supplementation
Description: Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
Study: NCT02659774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: workshop (Motivational intervention)
Description: Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
Study: NCT01887262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCM-guided fluid management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management based on the clinical information alone
Study: NCT02659774

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Face to Face counseling
Description: Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phone counseling
Description: Use motivational interview strategies through telephone counseling to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Use motivational interview strategies through telephone messages to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SMS
Description: Use motivational interview strategies through telephone messages to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SMS
Description: Use motivational interview strategies through telephone messages to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SMS
Description: Use motivational interview strategies through telephone messages to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
Study: NCT03012126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight Clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight and Your Child
Study: NCT00895102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-333 Tablet
Description: See Arm Description for more information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-333 Tablet
Description: See Arm Description for more information.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-333 Tablet
Description: See Arm Description for more information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: See Arm Description for more information.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Description for more information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-333 Capsule
Description: See arm description for more information
Study: NCT01295879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 50,000 IU's orally per week, for 8 weeks
Study: NCT02264145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From HFA134a-MDI - low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From HFA134a-MDI - medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From HFA134a-MDI - high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From Respimat®
Study: NCT00266786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketorolac Tromethamine
Description: Intranasal at 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal Placebo
Study: NCT04554836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients in Arm A will receive FOLFIRI +cetuximab.

Intervention type: OTHER
Group type: OTHER
Intervention: FOLFIRI
Description: Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
Study: NCT02683590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic Implant
Description: The replacement of the sternum by a ceramic implant
Study: NCT02730793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Aztreonam
Description: Standard Therapy Comparator (Oral Cayston 75mg three times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aztreonam
Description: Standard Therapy Comparator (Oral Cayston 75mg three times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Aztreonam
Description: Study Therapy (nasal Aztreonam 75mg twice per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Placebo
Description: Placebo (nasal saline twice per day)
Study: NCT01185353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally
Study: NCT02238535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventavis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT00275561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Aerosolized swallowed fluticasone 880 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaler swallowed twice a day for 6 weeks
Study: NCT02313831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Patients of this group will be submitted to an interval training program
Study: NCT04087226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE Retraction Cord
Description: Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTFE Retraction Cord
Description: Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
Study: NCT03121391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator withdrawal algorithm
Description: Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor
Study: NCT02093702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured Physical Activity and Exercise Education
Study: NCT02617238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular risk management based on PWV
Description: Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~1. In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~2. In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician
Study: NCT03939182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
Study: NCT01299766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Description: BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Therapy (ST)
Description: ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
Study: NCT01662440

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies
Description: Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies
Description: Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies
Description: Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis
Description: Subjects received two doses of Japanese Encephalitis vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis
Description: Subjects received two doses of Japanese Encephalitis vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis
Description: Subjects received two doses of Japanese Encephalitis vaccine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
Study: NCT02257580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-Aminocaproic acid
Description: E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E-Aminocaproic acid
Description: E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
Study: NCT03262363

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Curcumin/NFE2L2 A>G
Description: The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/NFE2L2 A>G
Description: The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
Study: NCT02788500

Intervention type: OTHER
Intervention: Incidence of sports-related injuries and illnesses
Description: The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
Study: NCT02766660

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: All groups were measured by optical coherence tomography.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: All groups were measured by optical coherence tomography.
Study: NCT03623724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended Cognitive-behavioral Therapy
Description: The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
Study: NCT00843908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tension Free Vaginal Tape
Description: Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniarc
Description: The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
Study: NCT03624257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal flap surgery
Description: The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
Study: NCT04158063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~* Titrated digit span backwards~* Auditory vigilance with alphabets~* Subtracting by 7~Motor tasks:~* Walking at self-selected speed~* Walking while carrying a cup of water~* Walking while stepping over obstacles~* Walking crisscross

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Mobility Training
Description: standard routine training
Study: NCT03064763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec will be administered as an intralesional injection.
Study: NCT01185353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally as background therapy
Study: NCT01284491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade 4.0
Description: The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
Study: NCT05172219

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Sent Outreach with Embedded Asynchronous Care in Portal Message
Description: PCPs sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Sent Outreach without Embedded Asynchronous Care in Portal Message
Description: Physician sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
Study: NCT01284491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
Study: NCT02212600

Intervention type: OTHER
Intervention: Observational
Description: observational cohort of proximal humerus fractures
Study: NCT01250444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
Study: NCT00127270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Darifenacin
Description: Darifenacin tablets 7,5 mg or 15 mg once daily